Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-κB subunits in head and neck cancer

Clinical Cancer Research

Volumn 14, Issue 13, 2008, Pages 4175-4185

  Allen, Clint ^a   Saigal, Kunal ^a   Nottingham, Liesl ^a   Arun, Pattatheyil ^a   Chen, Zhong ^a   Van Waes, Carter ^a,b  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DNA; PYRAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL DENSITY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA BINDING; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; LOW DRUG DOSE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR GROWTH; BIOLOGICAL MODEL; CELL FRACTIONATION; CELL NUCLEUS; CHEMISTRY; GENE EXPRESSION REGULATION; HEAD AND NECK TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RECURRENT DISEASE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; DNA; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; NF-KAPPA B; PHOSPHORYLATION; PYRAZINES; RECURRENCE; SIGNAL TRANSDUCTION; SUBCELLULAR FRACTIONS;

EID: 48249140693     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4470     Document Type: Article

References (42)

1. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
2. Chen ZJ. Ubiquitin signalling in the NF-κB pathway. Nat Cell Biol 2005;7:758-65.
3. Greten FR, Karin M. The IKK/NF-κB activation pathway-a target for prevention and treatment of cancer. Cancer Lett 2004;206:193-9.
4. Li ZW, Chu W, Hu Y, et al. The IKKβ subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis. J Exp Med 1999; 189:1839-45.
5. Sanjabi S. Williams KJ, Saccani S, et al. A c-Rel subdomain responsible for enhanced DNA-binding affinity and selective gene activation. Genes Dev 2005;19: 2138-51.
6. Xiao G, Harhaj EW, Sun SC. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol Cell 2001;7:401-9.
7. Basseres DS, Baldwin AS. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene 2006;25:6817-30.
8. Van Waes C. Nuclear factor-κB in development, prevention, and therapy of cancer. Clin Cancer Res 2007; 13:1076-82.
9. Ondrey FG, Dong G, Sunwoo J, et al. Constitutive activation of transcription factors NF-(κ)B, activator protein (AP-1), and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express proinflammatory and pro-angiogenic cytokines. Mol Carcinog 1999;26:119-29.
10. Duffey DC, Chen Z, Dong G, et al. Expression of a dominant-negative mutant inhibitor-κ-Bα of nuclear factor-KB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999; 59:3468-74.
11. Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C. Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2007; 6:37-50.
12. Dong G, Chen Z, Kato T, Van Waes C. The host environment promotes the constitutive activation of nuclear factor-κB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res 1999; 59:3495-504.
13. Loercher A, Lee TL, Ricker JL, et al. Nuclear factor- κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004;64:6511-23.
14. Zhang PL, Pellitteri PK, Law A, et al. Overexpression of phosphorylated nuclear factor-κ B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis. Mod Pathol 2005;18: 924-32.
15. Wolf JS, Chen Z, Dong G, et al. IL (interleukin)-1α promotes nuclear factor-κB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 2001;7:1812-20.
16. Bancroft CC, Chen Z, Yeh J, et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002;99:538-48.
17. Duffey DC, Crowl-Bancroft CV, Chen Z, et al. Inhibition of transcription factor nuclear factor-κB by a mutant inhibitor-h-Ba attenuates resistance of human head and neck squamous cell carcinoma to TNF-α caspase-mediated cell death. Br J Cancer 2000;83: 1367-74.
18. Jackson-Bernitsas DG, Ichikawa H, Takada Y, et al. Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-κB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene 2007;26:1385-97.
19. Sunwoo JB, Chen Z. Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-h B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma Clin Cancer Res 2001;7:1419-28.
20. Adams J, PalombellaVJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment Invest New Drugs 2000;18:109-21.
21. kappa;B pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-κB Ann Clin Lab Sci 2005;35:251-8.
22. Van Waes C, SJ, Degraff W, et al. Radiosensitization and proteasome inhibition. In: JA. editor. Cancer drug discovery and development: proteasome inhibitors in cancer therapy. Totowa: Humana Press; 2004.
23. Van Waes C, Chang AA, Lebowitz PF, et al Inhibition of nuclear factor-κ B and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-andneck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;63:1400-12.
24. Nenutil R, Smardova J, Pavlova S. et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry J Pathol 2005;207:251-9.
25. Carmichael J, DeGraff WG. Gazdar AF, Minna JD. Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 1987;47:943-6.
26. Bancroft CC, Chen Z, Dong G, et al. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-κB signal pathways. Clin Cancer Res 2001;7:435-42.
27. Song Jl, Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000;19:2489-95.
28. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Ciin Oncol 2004;22:2108-21.
29. Richmond A. Nf-κ B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002;2:664-74.
30. Mishra A, Bharti AC, Varghese P, Saluja D, Das BC. Differential expression and activation of NF-κB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection. Int J Cancer 2006; 119:2840-50.
31. Allen CT, Ricker JL, Chen Z, Van Waes C. Role of activated nuclear factor-κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck 2007;29:959-71.
32. LeeTL, Yeh J, Van Waes C, Chen Z. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol CancerTher 2006;5:8-19.
33. Yu M, Yeh J, Van Waes C. Protein kinase casein kinase 2 mediates inhibitor-κB kinase and aberrant nuclear factor-κB activation by serum factor(s) in head and neck squamous carcinoma cells. Cancer Res 2006;66:6722-31.
34. Van Waes C, Yu M, Nottingham L, Karin M. Inhibitor- κB Kinases in tumor promotion and suppression during progression of squamous cell carcinoma. Clin Cancer Res 2007;13:4956-9.
35. Kim KM, Zhang Y, Kim BY, et al. The p65 subunit of nuclear factor-κB is a molecular target for radiation sensitization of human squamous carcinoma cells. Mol CancerTher 2004;3:693-8.
36. Kurland JF, Kodym R, Story MD, Spurgers KB, McDonnell TJ, Meyn RE. NF-κB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. J Biol Chem 2001;276:45380-6.
37. Teni T, Pawar S, Sanghvi V, Saranath D. Expression of bcl-2 and bax in chewing tobacco-induced oral cancers and oral lesions from India. Pathol Oncol Res 2002;8:109-14.
38. Cheng S, Hsia CY, Leone G, Liou HC. Cyclin E and Bcl-xL cooperatively induce cell cycle progression in c-Rel-/- B cells. Oncogene 2003;22:8472-86.
39. Park SG, Chung C, Kang H, Kim JY, Jung G. Up-regulation of cyclin D1 by HBx is mediated by NF-κB2/BCL3 complex through κB site of cyclin D1 promoter. J Biol Chem 2006;281:31770-7.
40. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;18:6938-47.
41. Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin BiolTher 2006;6:231-41.
42. Squarize CH, Castilho RM, SriuranpongV, Pinto DS, Jr., Gutkind JS. Molecular cross-talk between the NFkB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 2006;8: 733-46.